CLS initiates recruitment process for permanent Chief Financial Officer

Clinical Laserthermia Systems (CLS) has launched a search for a permanent, full-time Chief Financial Officer to replace its interim part-time consulting CFO, citing a need to strengthen financial leadership, improve cost efficiency and create a scalable finance function to support continued growth, operational focus and international expansion. The interim CFO will remain during the recruitment; CLS, listed on Nasdaq First North Growth Market (CLS B), develops image-guided laser ablation systems (TRANBERG and ClearPoint Prism) for cancer and drug‑resistant epilepsy and says the hire is intended to bolster finance and governance as it scales across Germany, the US and Singapore (disclosure published 12‑Dec‑2025).

Analysis

Clinical Laserthermia Systems (CLS) has initiated recruitment for a permanent, full-time Chief Financial Officer to replace its current interim, part-time consulting CFO, and the interim CFO will remain in place during the search. CEO Dan Mogren states the hire is necessary as the business enters a stage requiring stronger financial leadership, improved cost efficiency and alignment with strategic priorities.

The company frames the appointment as a way to create a long-term, scalable finance function to support continued growth, operational focus and international expansion; CLS develops the TRANBERG Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables for image-guided laser ablation of cancer tumors and drug-resistant epilepsy and sells through partners across Germany, the United States and Singapore. A permanent CFO would likely be responsible for scaling partner relationships, cross-border finance operations and cost controls tied to that expansion.

CLS is listed on Nasdaq First North Growth Market (CLS B) and disclosed the search on 12‑Dec‑2025; the sentiment signal is mildly positive (0.25) with modest market impact (0.12), suggesting the market views the move as governance- and execution-positive but not transformational. Key near-term risks are recruitment delay and residual uncertainty in financial strategy until a permanent appointment is announced, so investors should monitor subsequent disclosures on timing, candidate profile and any changes to financial guidance or capital plans.

Key Decisions for Investors

• Monitor the CFO recruitment timeline and candidate qualifications closely, as appointment of an experienced, internationally-capable CFO would be a positive governance and execution signal
• Maintain positions or make only modest adjustments ahead of a hire given mildly positive sentiment and limited immediate market impact, avoiding large directional trades until the appointment and any strategic changes are disclosed
• Watch for follow-up disclosures that signal changes to cost structure, capital strategy or financial guidance after the hire, and consider reducing exposure or hedging if recruitment extends and uncertainty around financial leadership persists